NCT06028932 is a Phase 2 clinical trial of Sacituzumab govitecan in Ovarian Carcinoma, sponsored by Yale University.

Who is sponsoring NCT06028932?

NCT06028932 is sponsored by Yale University.

What drugs are being tested in NCT06028932?

Interventions in NCT06028932: Sacituzumab govitecan.

What condition does NCT06028932 study?

NCT06028932 studies Ovarian Carcinoma.

Is NCT06028932 still recruiting?

NCT06028932 is currently active, enrolled. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT06028932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Active, enrolled Phase 2 Last updated 5 March 2026

What this trial tests

Phase 2 trial testing Sacituzumab govitecan in Ovarian Carcinoma in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 January 2024

Primary endpoint
1 November 2026

1 November 2027

Quick facts

Lead sponsor	Yale University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 January 2024
Primary completion	1 November 2026
Estimated completion	1 November 2027
Sites	1 location across United States

Drugs / interventions tested

Sacituzumab govitecan — full drug profile →

Conditions studied

Ovarian Carcinoma — all drugs for Ovarian Carcinoma →

Sponsor

Yale University

Who can join

18 and older, female only, with Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.
Sato S, Shoji T, Jo A, Otsuka H, et al · · 2024 · cited 10× · PMID 39061184 · DOI 10.3390/cancers16142545
Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives.
Papageorgiou D, Liouta G, Pliakou E, Zachariou E, et al · · 2025 · cited 5× · PMID 40722601 · DOI 10.3390/biomedicines13071525
Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers.
Ettorre VM, AlAshqar A, Sethi N, Santin AD. · · 2025 · cited 2× · PMID 40507303 · DOI 10.3390/cancers17111822
Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.
Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, et al · · 2024 · cited 2× · PMID 39108617 · DOI 10.1016/j.gore.2024.101459
TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms.
Eroles P, Dawid de Vera MT, Lago V. · · 2026 · PMID 42040770 · DOI 10.20517/cdr.2025.195
Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.
Ettorre VM, Greenman M, Palmieri L, Demirkiran C, et al · · 2025 · PMID 41257122 · DOI 10.7759/cureus.94784

Verify or expand the search:

Other trials of Sacituzumab govitecan

Trials testing the same drug.

NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07178730 — NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple- · Phase 3 · not yet recruiting
NCT07011654 — Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) · Phase 1, PHASE2 · recruiting
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting

Other recruiting trials for Ovarian Carcinoma

Currently open trials in the same condition.

NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06964009 — DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · Phase 1 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06028932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06028932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing